Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 2/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5738486 | 0.88 | FFAR1 (0.42) | ACACB | |
| SCHEMBL6426393 | 0.82 | PTGS2 (0.36) | HSP90AA1HSP90AB1BACE1ACACB | |
| SCHEMBL5735225 | 0.80 | ACACB (0.40) | ACACB | |
| SCHEMBL5736752 | 0.79 | GABRA1 (0.31) | — | |
| SCHEMBL5736640 | 0.76 | BACE1 (0.31) | BACE1 | |
| SCHEMBL7202315 | 0.75 | CYP26A1 (0.30) | ACACB | |
| SCHEMBL6155420 | 0.68 | ACACB (0.43) | BACE1ACACB | |
| SCHEMBL5737430 | 0.67 | HSD11B1 (0.37) | BACE1 | |
| SCHEMBL6885569 | 0.67 | FFAR1 (0.46) | — | |
| SCHEMBL7224755 | 0.67 | CA12 (0.39) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6603019-B2 | Phenylacetic or heteroarylacetic acid derivatives, retinoic acid inducible enzyme, used to treat diseases responsive to retinoids | ALLERGAN, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020156082-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ROLR, INC. | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156082-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | RARA, RARB, RARG | HSP90AA1 1050/4885HSP90AB1 819/4885BACE1 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.